Skip to main content

Vamsidhar Velcheti, MD

  • Specialty: Medical Oncology
  • Language: English
  • Phone: 212-731-5662
View Locations

About Me

It is an extremely gratifying experience to help patients and their families navigate through the complexities of cancer care. My patients’ stories of courage, resilience, and determination are a source of inspiration for me and my team to continually provide the highest quality of care.

As director of thoracic medical oncology at NYU Langone’s Perlmutter Cancer Center, I specialize in treating patients who have thoracic malignancies, such as lung cancer and mesothelioma. Our team at Perlmutter Cancer Center offers patients the most advanced treatments, including immunotherapy and targeted therapy, and develops novel therapies through clinical trials.

Lung cancer is a complex disease and requires a group effort to meet the many needs of our patients. We have an outstanding team of medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, pathologists, radiologists, and researchers at our Lung Cancer Center. This allows us to provide the best care for our patients and offer some of the most innovative treatment approaches in the form of clinical trials.

For me, conquering cancer means offering people hope and giving them new opportunities. It’s an incredible feeling to be part of a team that can make a difference in someone’s life. Over the last few years, we have seen a paradigm shift in our understanding of the biology of cancer. We are able to deliver personalized treatments for patients based on a better understanding of the genetic makeup of the patient’s tumor, which offers an improved chance of success. But I believe personalized medicine goes beyond just providing customized treatment plans—it involves understanding that patients may have varying physical, cognitive, and social needs. To meet every person’s unique needs and provide the best patient experience, it is important to consider the patient and caregiver’s circumstances as they cope with the diagnosis and begin treatment.

My research focuses on developing novel treatments called immunotherapy that can empower the patient’s immune system to fight cancer and discovering biomarkers to predict which patients could benefit from immunotherapy. I have lectured at national and international meetings and have been the recipient of several awards by the American Society of Clinical Oncology, including the Young Investigator Award in 2012, the Merit Award in 2013, and the Career Development Award in 2015.

Conditions and Treatments

lung cancer, non-small cell lung cancer, small cell lung cancer, adenoid cystic carcinoma of the lung, lung carcinoma, mediastinal tumor, mesothelioma, mucoepidermoid carcinoma of the lung, neuroendocrine tumor of the lung, thoracic cancer, thymus cancer
Show More Conditions


  • Member of the Faculty, Department of Medicine
  • Director, Thoracic Med Oncology Program
Board Certifications
  • American Board of Internal Medicine - Internal Medicine, 2010
Education and Training
  • Fellowship, Yale University - School of Medicine, Hematology Oncology, 2013
  • Residency, Ochsner Foundation Hospital, Internal Medicine, 2010
  • MD from Armed Forces Medical College, 2003

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Locations and Appointments

View Insurance Plans Accepted
  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Centerlight
    • Centerlight
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Emblem
    • Emblem Select Care Exchange
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
    • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Family Health
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
    • GHI HMO
  • HIP
    • HIP Access I
    • HIP Access II
    • HIP Child Health
    • HIP Essential
    • HIP HMO
    • HIP Medicaid
    • HIP Medicare
    • HIP POS
  • Hotel Trades
    • Hotel Trades
  • Humana
    • Humana Medicare
  • MagnaCare
    • MagnaCare PPO
  • Medicaid
    • NY Medicaid
  • Medicare
    • Medicare
  • MetroPlus
    • MetroPlus Child Health
    • MetroPlus Essential
    • MetroPlus Exchange Plans
    • MetroPlus Family Health
    • MetroPlus Medicaid
    • MetroPlus Medicare
  • MultiPlan/PHCS
    • MultiPlan/PHCS PPO
  • NYS Health Insurance Plan
    • The Empire Plan
  • Oxford
    • Oxford Freedom
    • Oxford Liberty
    • Oxford Medicare
  • PHP
    • PHP
  • Railroad Medicare
    • Railroad Medicare
  • Tricare
    • Tricare
  • UHC
    • UnitedHealthcare Community & State Plan
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare Medicare
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
  • VNS
    • Visiting Nurse Service (VNS) Medicare
  • Village Caremax
    • Village Caremax
NYU Medical Oncology Associates

160 East 34th Street, 8th Floor
New York, NY 10016

Clinical Trials and Research Studies

  • A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors Including RET Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-001)

    Learn More
  • A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

    Learn More
View All Research Studies (5)


Read All Publications (82)

Related News

We can help you find a doctor. Call 646-929-7800 or
browse our specialists.